Torrent Pharmaceuticals Ltd has secured final listing and trading approval for 4,19,22,416 fully paid-up equity shares issued pursuant to its Scheme of Amalgamation with J. B. Chemicals & Pharmaceuticals Limited. The new shares will begin trading on the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) effective July 28, 2026, marking a key procedural milestone in the consolidation of the two pharmaceutical entities.

The approval follows the allotment of these shares to eligible shareholders of J. B. Chemicals & Pharmaceuticals Limited based on the record date of Friday, July 17, 2026. Each share carries a face value of ₹ 5/-. The company had previously intimated the allotment details on July 20, 2026, confirming that the issuance was completed in accordance with the approved scheme.

Transaction Details

The following table outlines the key parameters of the share issuance and listing event:

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Ltd, signed the communication confirming receipt of the approvals from both exchanges on July 27, 2026.

What This Means for Shareholders

For former shareholders of J. B. Chemicals & Pharmaceuticals Limited, the commencement of trading on July 28, 2026, allows for the liquidation or holding of their converted equity stake in Torrent Pharmaceuticals Ltd. The seamless transition from allotment to listing indicates that all regulatory and exchange requirements for the amalgamation have been satisfied. Investors should monitor market movements during the initial trading sessions to assess price discovery for the newly listed shares.

Torrent Pharmaceuticals has voluntarily dissolved its wholly owned subsidiary, Curatio Inc., in the Philippines, effective July 10, 2026. The company received official communication regarding the dissolution on July 17, 2026. The subsidiary was domiciled in the Philippines and ceased operations through the shortening of its term of existence via an amendment to its Articles of Incorporation.

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The dissolution was not part of a slump sale, and no consideration was received as the entity was dissolved rather than sold.

Financial details of the subsidiary for the last financial year indicate minimal contribution to the parent company's overall operations. As of March 31, 2026, the unit had recorded nil turnover.

Financial Impact of Dissolution

The following table outlines the financial position of the subsidiary prior to its dissolution:

The dissolution does not involve any related party transactions or a sale outside a Scheme of Arrangement. Consequently, the closure is not expected to have a material financial impact on Torrent Pharmaceuticals, given the subsidiary's negligible revenue contribution.